Molecular imaging of obsessive–compulsive disorder

doi:10.1017/CBO9780511782091.019

18 - Molecular imaging of obsessive–compulsive disorder

from Section III - Anxiety Disorders

Published online by Cambridge University Press: 10 January 2011

Martijn Figee ,

Jan Booij and

Damiaan Denys

Edited by

Martha E. Shenton and

Bruce I. Turetsky

Show author details

Martijn Figee: Affiliation:
Department of Psychiatry University of Amsterdam Amsterdam, The Netherlands
Jan Booij: Affiliation:
Department of Nuclear Medicine University of Amsterdam Amsterdam, The Netherlands
Damiaan Denys: Affiliation:
Department of Psychiatry University of Amsterdam Amsterdam, The Netherlands
Martha E. Shenton: Affiliation:
VA Boston Healthcare System and Brigham and Women's Hospital, Harvard Medical School
Bruce I. Turetsky: Affiliation:
University of Pennsylvania

Book contents

Get access

Summary

Introduction

Obsessive–compulsive disorder (OCD) is a chronic psychiatric disorder that is characterized by the presence of recurrent and anxiety-provoking thoughts, images or impulses (obsessions), typically followed by repetitive ritualistic behaviors (compulsions) to relieve anxiety. The prevalence of OCD is estimated to be between 1 and 3% (Ruscio et al.,2010; Fullana et al., 2009). Without adequate treatment, obsessions and compulsions can become extremely time-consuming, causing significant impairments in social and occupational functioning. Effective treatment options for OCD are cognitive behavioral therapy, pharmacotherapy or psychosurgical interventions.

Approximately 40–60% of OCD patients respond to pharmacotherapy with drugs that increase intrasynaptic serotonin (Denys 2006; Soomro et al., 2008). Hence, it is often suggested that OCD is related to a dysfunction of brain serotonin systems. Central dopaminergic systems are likely to be involved as well, since patients who do not respond to treatment with serotonin reuptake inhibitors (SRIs) can be successfully augmented with dopamine receptor antagonists (Fineberg et al., 2006; Bloch et al., 2006). Finally, the potential efficacy of glutamate modulating drugs in OCD (Denys, 2006) suggests glutaminergic abnormalities in OCD.

Functional imaging studies indicate involvement of the cortico-striatal–thalamic–cortical circuit in OCD pathophysiology (Saxena and Rauch, 2000; Menzies et al., 2008) and within this circuitry, the neurotransmitters serotonin, dopamine and glutamate are important regulators of neuronal activity. The exact function of these neurotransmitters in OCD is still unclear, however. They may be directly implicated in the pathophysiology of OCD, or only related to treatment effects.

Keywords

1H magnetic resonance spectroscopy obsessive-compulsive disorder positron emission tomography single photon emission computed tomography serotonin transporter serotonergic neurotransmission serotonin reuptake inhibitors

Type: Chapter
Information: Understanding Neuropsychiatric Disorders
Insights from Neuroimaging
, pp. 260 - 273

DOI: https://doi.org/10.1017/CBO9780511782091.019 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adams, K H, Hansen, E S, Pinborg, L H, et al. 2005. Patients with obsessive–compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int. J. Neuropsychopharmacol 8, 391–401.Google Scholar

Becquet, D, Faudon, M and Hery, F. 1990. In vivo evidence for an inhibitory glutamatergic control of serotonin release in the cat caudate nucleus: Involvement of GABA neurons. Brain Res 519, 82–8.Google Scholar

Benmansour, S, Owens, W A, Cecchi, M, Morilak, D A and Frazer, A. 2002. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 22, 6766–72.Google Scholar

Bloch, M H, Landeros-Weisenberger, A, Kelmendi, B, Coric, V, Bracken, M B and Leckman, J F. 2006. A systematic review: Antipsychotic augmentation with treatment refractory obsessive–compulsive disorder. Mol Psychiatry 11, 622–32.Google Scholar

Booij, J, Jong, J, Bruin, K, Knol, R J J, Win, M M and Eck-Smit, B L F. 2007. Quantification of striatal dopamine transporters with [123I] beta-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: A double-blind, placebo-controlled, crossover study in healthy controls. J Nucl Med 48, 359–66.Google Scholar

Denys, D. 2006. Pharmacotherapy of obsessive–compulsive disorder and obsessive–compulsive spectrum disorders. Psychiatr Clin North Am 29, 553–84, xi.Google Scholar

Denys, D, Klompmakers, A A and Westenberg, H G. 2004. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl) 176, 195–203.Google Scholar

Dewey, S L, Smith, G S, Logan, J, et al. 1995. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15, 821–9.Google Scholar

Fineberg, N A, Gale, T M and Sivakumaran, T. 2006. A review of antipsychotics in the treatment of obsessive compulsive disorder. J Psychopharmacol 20, 97–103.Google Scholar

Fletcher, P J, Korth, K M and Chambers, J W. 1999. Selective destruction of brain serotonin neurons by 5,7-dihydroxytryptamine increases responding for a conditioned reward. Psychopharmacology (Berl) 147, 291–9.Google Scholar

Fowler, J S, Wang, G J, Volkow, N D, et al. 1999. PET studies of the effect of the antidepressant drugs nefazodone or paroxetine on [11C]raclopride binding in human brain. Clin Positron Imaging 2, 205–09.Google Scholar

Fullana, M A, Mataix-Cols, D, Caspi, A, et al. 2009. Obsessions and compulsions in the community: Prevalence, interference, help-seeking, developmental stability, and co-occurring psychiatric conditions. Am J Psychiatry 166, 329–36.Google Scholar

Gray, J A and Roth, B L. 2001. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56, 441–51.Google Scholar

Hasselbalch, S G, Hansen, E S, Jacobsen, T B, Pinborg, L H, Lønborg, J H and Bolwig, T G. 2007. Reduced midbrain-pons serotonin transporter binding in patients with obsessive–compulsive disorder. Acta Psychiatr Scand 115, 388–94.Google Scholar

Hesse, S, Muller, U, Lincke, T, et al. 2005. Serotonin and dopamine transporter imaging in patients with obsessive–compulsive disorder. Psychiatry Res 140, 63–72.Google Scholar

Kapur, S and Remington, G. 1996. Serotonin–dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153, 466–76.Google Scholar

Kim, C H, Cheon, K A, Koo, M S, et al. 2007. Dopamine transporter density in the basal ganglia in obsessive–compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology 55, 156–62.Google Scholar

Kim, C H, Koo, M S, Cheon, K A, Ryu, Y H, Lee, J D, Lee, H S. 2003. Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive–compulsive disorder. Eur J Nucl Med Mol Imaging 30, 1637–43.Google Scholar

Koch, S, Perry, K W, Nelson, D L, Conway, R G, Threlkeld, P G and Bymaster, F P. 2002. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: An in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27, 949–59.Google Scholar

Laruelle, M, Baldwin, R M, Malison, R T, et al. 1993. SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT: Pharmacological characterization of brain uptake in nonhuman primates. Synapse 13, 295–309.Google Scholar

Laruelle, M, Wallace, E, Seibyl, J P, et al. 1994. Graphical, kinetic, and equilibrium analyses of in vivo [123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 14, 982–94.Google Scholar

Malison, R T, Price, L H, Berman, R, et al. 1998. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2bcarbomethoxy-3b-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 44, 1090–8.Google Scholar

Menzies, L, Chamberlain, S R, Laird, A R, Thelen, S M, Sahakian, B J and Bullmore, E T. 2008. Integrating evidence from neuroimaging and neuropsychological studies of obsessive compulsive disorder: The orbitofronto-striatal model revisited. Neurosci Biobehav Rev 32, 525–49.Google Scholar

Moore, G J, MacMaster, F P, Stewart, C and Rosenberg, D R. 1998. Case study: Caudate glutamatergic changes with paroxetine therapy for paediatric obsessive–compulsive disorder. J Am Acad Child Adolesc Psychiatry 37, 663–7.Google Scholar

Moresco, R M, Pietra, L, Henin, M, et al. 2007. Fluvoxamine treatment and D2 receptors: A PET study on OCD drug-naïve patients. Neuropsychopharmacology 32, 197–205.Google Scholar

Olver, J S, O'Keefe, G, Jones, G R, et al. 2009. Dopamine D(1) receptor binding in the striatum of patients with obsessive–compulsive disorder. J Affect Disord 114, 321–6.Google Scholar

Olvera-Cortés, M E, Anguiano-Rodríguez, P, López-Vázquez, M A and Alfaro, J M. 2008. Serotonin/dopamine interaction in learning. Prog Brain Res 172, 567–602.Google Scholar

Perani, D, Garibotto, V, Gorini, A, et al. 2008. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naïve obsessive–compulsive disorder. Neuroimage 42, 306–14.Google Scholar

Pfund, Z, Chugani, D C, Juhasz, C, et al. 2000. Evidence for coupling between glucose metabolism and glutamate cycling using FDG PET and 1H magnetic resonance spectroscopy in patients with epilepsy. J Cerebr Blood Flow Metab 20, 871–8.Google Scholar

Pirker, W, Asenbaum, S, Hauk, M, et al. 2000. Imaging serotonin and dopamine transporters with 123I-β-CIT SPECT: Binding kinetics and effects of normal aging. J Nucl Med 41, 36–44.Google Scholar

Pogarell, O, Hamann, C, Popperl, G, et al. 2003. Elevated brain serotonin transporter availability in patients with obsessive–compulsive disorder. Biol Psychiatry 54, 1406–13.Google Scholar

Pogarell, O, Poepperl, G, Mulert, C, et al. 2005. SERT and DAT availabilities under citalopram treatment in obsessive–compulsive disorder (OCD). Eur Neuropsychopharmacol 15, 521–4.Google Scholar

Reimold, M, Smolka, M N, Zimmer, A, et al. 2007. Reduced availability of serotonin transporters in obsessive–compulsive disorder correlates with symptom severity – A [11C]DASB PET study. J Neural Transm 114, 1603–09.Google Scholar

Rosario-Campos, M C, Leckman, J F, Mercadante, M T, et al. 2001. Adults with early-onset obsessive–compulsive disorder. Am J Psychiatry 158, 1899–903.Google Scholar

Rosenberg, D R, MacMaster, F P, Keshavan, M S, Fitzgerald, K D and Stewart, C M. 2000. Decrease in caudate glutamatergic concentrations in paediatric obsessive–compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39, 1096–103.Google Scholar

Rosenberg, D R, Mirza, Y, Russell, A, et al. 2004. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 43, 1146–53.Google Scholar

Ruscio, A M, Stein, D J, Chiu, W T and Kessler, R C. 2010. The epidemiology of obsessive–compulsive disorder in the National Comorbidity Survey Replication Mol Psychiatry 15, 53–63.Google Scholar

Saiz, P A, Garcia-Portilla, M P, Arango, C, et al. 2008. Association study between obsessive–compulsive disorder and serotonergic candidate genes. Prog Neuropsychopharmacol Biol Psychiatry 32, 765–70.Google Scholar

Saxena, S and Rauch, S L. 2000. Functional neuroimaging and the neuroanatomy of obsessive–compulsive disorder. Psychiatr Clin North Am 23, 563–86.Google Scholar

Schneier, F R, Liebowitz, M R, Abi-Dargham, A, Zea-Ponce, Y, Lin, S H and Laruelle, M. 2000. Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry 157, 457–9.Google Scholar

Schneier, F R, Martinez, D, Abi-Dargham, A, et al. 2008. Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings. Depress Anxiety 25, 1–7.Google Scholar

Schultz, W. 1998. Predictive reward signal of dopamine neurons. J Neurophysiol 80, 1–27.Google Scholar

Simpson, H B, Lombardo, I, Slifstein, M, et al. 2003. Serotonin transporters in obsessive–compulsive disorder: A positron emission tomography study with [11C]McN 5652. Biol Psychiatry 54, 1414–21.Google Scholar

Smith, G S, Dewey, S L, Brodie, J D, et al. 1997. Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects. Am J Psychiatry 154, 490–6.Google Scholar

Soomro, G M, Altman, D, Rajagopal, S and Oakley-Browne, M. 2008. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 1, CD001765.

Starck, G, Ljungberg, M, Nilsson, M, et al. 2008. A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. J Neural Transm 115, 1051–62.Google Scholar

Stengler-Wenzke, K, Müller, U, Angermeyer, M C, Sabri, O and Hesse, S. 2004. Reduced serotonin transporter availability in obsessive–compulsive disorder (OCD). Eur Arch Psychiatry Clin Neurosci 254, 252–5.Google Scholar

Stengler-Wenzke, K, Müller, U, Barthel, H, Angermeyer, M C, Sabri, O and Hesse, S. 2006. Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive–compulsive disorder. Neuropsychobiology 53, 40–5.Google Scholar

Wee, N J, Stevens, H, Hardeman, J A, et al. 2004. Enhanced dopamine transporter density in psychotropic-naïve patients with obsessive–compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry 161, 2201–06.Google Scholar

Whiteside, S P, Port, J D, Deacon, B J and Abramowitz, J S. 2006. A magnetic resonance spectroscopy investigation of obsessive–compulsive disorder and anxiety. Psychiatry Res. 146, 137–47.Google Scholar

Wong, D F, Brašic, J R, Singer, H S, et al. 2008. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette Syndrome: Clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 33, 1239–51.Google Scholar

Yücel, M, Wood, S J, Wellard, R M, et al. 2008. Anterior cingulate glutamate–glutamine levels predict symptom severity in women with obsessive–compulsive disorder. Aust N Z J Psychiatry 42, 467–77.Google Scholar

Zhou, F M, Liang, Y, Salas, R, Zhang, L, Biasi, M and Dani, J A. 2005. Corelease of dopamine and serotonin from striatal dopamine terminals. Neuron 46, 65–74.Google Scholar

Zitterl, W, Aigner, M, Stompe, T, et al. 2007. [123I]-beta-CIT SPECT imaging shows reduced thalamus–hypothalamus serotonin transporter availability in 24 drugfree obsessive–compulsive checkers. Neuropsychopharmacology 32, 1661–8.Google Scholar

Zitterl, W, Aigner, M, Stompe, T, et al. 2008. Changes in thalamus–hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive–compulsive disorder. Neuropsychopharmacology 33, 3126–34.Google Scholar

Book contents

18 - Molecular imaging of obsessive–compulsive disorder

Summary

Keywords

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive